Arena Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 81,394 27,587 12,719 16,613
Cost of Revenue 6,180 3,671 8,100 7,414
Gross Profit 75,214 23,916 4,619 9,199
Operating Expenses
Research and Development 66,468 54,112 58,706 75,459
Sales, General and Admin. 31,681 26,226 24,248 27,936
Non-Recurring Items - - 3,467 -
Other - 691 997 2,159
Operating Income (22,935) (57,113) (82,799) (96,355)
Income From Continuing Operations
Add'l Income/Expense Items 10,591 (19,244) (12,116) (6,498)
Earnings Before Interest and Tax (12,344) (70,019) (84,401) (102,853)
Interest Expense 7,091 9,120 14,309 21,681
Earnings Before Tax (19,435) (79,139) (98,710) (124,534)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (19,435) (85,477) (109,224) (136,888)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (19,435) (85,477) (109,224) (124,534)
Preferred Stock and Other Adjustments - (2,824) (2,260) -
Net Income Applicable to Common Shareholders (19,435) (88,301) (111,484) (124,534)